Evaluation of Paclitaxel Effects in The Pattern of Expression of Survival and Apoptotic Genes Regulators in HeLa Cells.

In this study, the anti-tumor effects of Paclitaxel (PAC) on HeLa cells have been studied in order to determine the cellular and molecular mechanisms of these effects. PAC has been applied to HeLa cells in 6 different doses (3, 7.5, 15, 30, 60, 120 nM) for 48 hours and the IC50 dose MTT method, has been determined with apoptic index (AI) DAPI. Morphological aspects have been demonstrated using light, phase contrast and fluorescent microscopes, additionally activation of Caspase3,7 and 10 have been shown using florescent spectroscopy. RT-PCR and qRT-PCR have been used to evaluate pro/anti-apoptotic gene expression. According to the parameters being evaluated; PAC has reduced cell multiplication based on dosage and time (p<0.01). 15 nM has been determined as the IC50 value. AI value has been determined as 42%. In the molecular level analyses in addition to the increase in Caspase3,7,10 activation, RT-PCR results show that bax, bak, bcl-x, bik, mcl-1 genes are expressed in the control group as well as the experimental 15 nM group; whereas bak, bcl-x ve bik genes have a decrease in expression compared to the control group. qRT-PCR results show that Apaf1, Bad, Bax, Bcl2L11, Caspase1, Caspase10, Caspase4, Caspase7, Dffa, Fas, Htra2, Lrdd, NFKB1, NFKB2, PMAIP1, RELA, RELB, TNFRSF10A, TNFRSF10C, TNFRSF10D, TNFRSF1A, TNFRSF21, TNFRSF25 gene expressions have increased significantly. On the other hand, BAG1, BBC3, Bcl2L1, Bcl2L10, Bid, Caspase2, Caspase6, Caspase8, Caspase9, FAD...
Source: Current Pharmaceutical Biotechnology - Category: Biotechnology Authors: Tags: Curr Pharm Biotechnol Source Type: research